CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
Condition(s):SARLast Updated:April 18, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):SARLast Updated:April 18, 2023Recruiting
Condition(s):Solid Tumor; Gastric Cancer; Breast Cancer; Ovarian Cancer; SarcomaLast Updated:April 18, 2023Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:June 22, 2023Not yet recruiting
Condition(s):SIOD; Cystinosis; FSGS; SLE Nephritis; CKD Stage 4Last Updated:July 17, 2023Recruiting
Condition(s):Indolent Non Hodgkin’s Lymphoma (iNHL); Chronic Lymphocytic Leukaemia (CLL)Last Updated:June 21, 2016Terminated
Condition(s):Leukemia, Myeloid, Acute; MDS; Hematopoietic Stem Cell Transplantation; Myeloid MalignancyLast Updated:November 28, 2023Recruiting
Condition(s):Hemophilia ALast Updated:December 23, 2022Recruiting
Condition(s):Aplastic Anemia IdiopathicLast Updated:August 11, 2020Unknown status
Condition(s):Hematologic NeoplasmsLast Updated:April 17, 2019Completed
Condition(s):Renal Cell CarcinomaLast Updated:October 21, 2021Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.